Virus Analysts

Born in Novorossiysk, Russia, Eugene graduated from the Institute of Cryptography, Telecommunications and Computer Science and worked at a multi-disciplinary scientific research institute until 1991. He began studying computer viruses in 1989, when the Cascade virus was detected on his computer.

From 1991 to 1997 Eugene worked at the KAMI Information Technologies Center where he developed the AVP antivirus project with a group of associates (AVP was renamed Kaspersky Anti-Virus in November 2000). Eugene Kaspersky became a co-founder of Kaspersky Lab in 1997.

Today, Eugene Kaspersky is one of the world's leading experts in the information security field. He has written a large number of articles and reviews related to computer virology and speaks regularly at specialized seminars and conferences all over the world.

Marc Blanchard is responsible for the European Virus Research Center, which undertakes real-time monitoring of the virus situation in Europe, and also conducts research into antivirus technology. In addition to his duties as head of the Center, Marc is also developing the technical support network for France.

Marc is one of the most distinguished computer virus experts in Europe, and has been working as an IT threat analyst since 1986, when he created his own technology against malicious software. Since then, he has headed the European research division at Central Point Software, been a leading figure in the creation of a French Computer Virus Research Center, and has published widely. Many of his publications are now used to train antivirus professionals, and he is active in educating the new generation of virus analysts.

David has been with Kaspersky Lab since April 2004, and provides information on viruses and other security threats through presentations and at exhibitions, and by talking with the mass media. He also provides information on Kaspersky Lab products and technology.

David has worked in the security industry for more than 14 years and has developed in-depth knowledge of the business and technical issues facing individual and corporate users during successive generations of viruses, worms and other malicious threats.

David joined Dr Solomon's Software in 1990, playing various roles in the years that followed, including Technical Support Manager and Senior Technology Consultant. During this time, he was responsible for establishing and running Dr Solomon's Technical Support department and was closely involved with customer seminars and technical training, including Dr Solomon's Live Virus Workshop. Following the acquisition of Dr Solomon's by Network Associates, David worked as a Systems Engineer and Product Manager, before joining the Product Marketing team in January 2001, where he was in charge of strategic marketing direction, product positioning and messaging for McAfee AVERT, scan engine and Internet gateway appliances.

Aleks became interested in fighting malware in 1994, when the company he worked at first installed an antivirus program. He began collecting virus samples and helping friends remove viruses from their PCs. From time to time, he found malicious programs as yet unknown to antivirus companies, and sent samples to Eugene Kaspersky, whose solution he liked because of its high detection rates.

In 1996, Alexander founded the Republic of Komi Anti-Virus Center and began publishing information on newly discovered viruses. He also provided consulting services and published an enewsletter to help colleagues fight malware. In 1998, the Wildlist Russia Project was launched with the objective of collecting and analyzing information about virus outbreaks in the Russian Federation. Aleks served as the project coordinator.

In 2002, Aleks joined the Virus Lab at Kaspersky Lab. His responsibilities include analyzing malicious software and detecting new malware. He is also involved in other research and publishes analyses on dedicated websites and in the press.

Magnus Kalkuhl was born in Copenhagen, and has worked in the IT industry since 1996. He has worked as an independent IT security consultant, and also as a Technical Director in the interactive department of McCann Erickson, a major advertising agency.

Magnus is based at Kaspersky Lab's German office. He will be focusing on IT forensics and research as well as monitoring the malware situation in Germany, Austria and Switzerland.

Yury Mashevsky was born in Smolensk, and completed his undergraduate degree in 1998 at the Smolensk branch of Moscow Energy Institute (Technical University). He received his PhD in May 2004 from the Moscow Energy Institute in Moscow for his dissertation on information security.

Before joining Kaspersky Lab in 2003, he worked as an information security systems developer for a small IT company based in Moscow, focusing on protecting information against theft and unauthorized analysis. While working in this field, he became interested in virus analysis.

Costin Raiu has been involved in antivirus research and the development of antivirus technologies for more than 9 years. He is a member of the Virus Bulletin Technical Advisory Board and CARO. Costin also provides his services as an incident reporter to The Wildlist Organization International and has written and published extensively on data security and computer viruses.

In 1994, Costin joined GeCAD s.r.l, as Chief Researcher and Data Security Expert in the Romanian AntiVirus (RAV) Team, where he was responsible for product development. Since 2000, Costin has been working with Kaspersky Lab, where he concentrates on new antivirus technology development, and security and monitoring research.

Roel was born in St. Odiliënberg, the Netherlands and has always been fascinated by all aspects of information security.

When his antivirus solution failed, this fascination grew, and he decided to take a closer look at the world of viruses and antiviruses. This quickly became a passion.

He joined Kaspersky Lab in 2004, where his current responsibilities include monitoring the malware situation in the region, preliminary analysis of malware and developing treatment for new viruses.